Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc - Ordinary Shares

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a Phas...

Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential

Abivax ($ABVX), a French biotech firm, has become the top acquisition candidate among biotechs in 2026, according to a Truist Securities ($TFC) sur...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$81.19	+1.15%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVMD	$81.19	+1.1%	1.40M
3
4
5
6

RVMD

RVMD

Latest News for RVMD

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

Get Revolution Medicines Inc - Ordinary Shares Data in Excel